FHFelix J.F. Herth

Felix J.F. Herth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Felix J.F. Herth has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction

    by the VENT Study Group, Charlie Strange, Felix Jf Herth, Kevin L Kovitz, Geoffrey McLennan, Armin Ernst, Jonathan Goldin, Marc Noppen, Gerard J Criner, Frank C Sciurba

    Lung volume reduction surgery is effective at improving lung function, quality of life, and mortality in carefully selected individuals with advanced emphysema. Recently, less invasive bronchoscopic approaches have been designed to utilize these principles while avoiding the associated perioperative risks. The Endobronchial Valve for Emphysema PalliatioN Trial (VENT) posits that occlusion of a single pulmonary lobe through bronchoscopically placed Zephyr® endobronchial valves will effect significant improvements in lung function and exercise tolerance with an acceptable risk profile in advanced emphysema. The trial design posted on Clinical trials.gov, on August 10, 2005 proposed an enrollment of 270 subjects. Inclusion criteria included: diagnosis of emphysema with forced expiratory volume in one second (FEV1) < 45% of predicted, hyperinflation (total lung capacity measured by body plethysmography > 100%; residual volume > 150% predicted), and heterogeneous emphysema defined using a quantitative chest computed tomography algorithm. Following standardized pulmonary rehabilitation, patients were randomized 2:1 to receive unilateral lobar placement of endobronchial valves plus optimal medical management or optimal medical management alone. The co-primary endpoint was the mean percent change in FEV1 and six minute walk distance at 180 days. Secondary end-points included mean percent change in St. George's Respiratory Questionnaire score and the mean absolute changes in the maximal work load measured by cycle ergometry, dyspnea (mMRC) score, and total oxygen use per day. Per patient response rates in clinically significant improvement/maintenance of FEV1 and six minute walk distance and technical success rates of valve placement were recorded. Apriori response predictors based on quantitative CT and lung physiology were defined. If endobronchial valves improve FEV1 and health status with an acceptable safety profile in advanced emphysema, they would offer a novel intervention for this progressive and debilitating disease. ClinicalTrials.gov: NCT00129584


  • Effects of Self-Expanding Metal Stents on Work of Breathing in Patients With Tracheobronchial Stenosis

    by Felix J. F Md Herth, Ralf Eberhardt, Heinrich D Becker

    Background: Obstructive stenosis of the airways can lead to symptoms ranging from fatigue to respiratory failure. Airway stents are frequently used to alleviate these symptoms. Conventional pulmonary function tests have been unsatisfactory as a sole measure of success in airway recanalization. We assessed the value of the work of breathing (WOB) as an outcome for studies investigating airway interventions. Methods: In a prospective investigation, we analyzed WOB before and after airway recanalization with implantation of self-expanding metal stents and compared these results with those of conventional pulmonary function tests. Results: During calendar year 2001, 44 patients (25 men; mean age 63 years; range, 29–88 years) underwent placement with a self-expandable metal stent placement. Reasons for stenting were a malignant stenosis in 33 (75%) and a benign airway stenosis in 11 (25%) cases. Stenting significantly reduced WOB, from 0.98 J/L to 0.66 J/L (95% confidence interval for the 0.32-J/l difference, P = 0.001). Results were most pronounced in patients with tracheal lesions. Summary: Self-expanding metal stents can substantially reduce WOB in patients with tracheobronchial stenosis. Work of breathing could be a worthwhile outcome parameter for evaluating the effect of airway interventions.


  • Autofluorescence Bronchoscopy – A Comparison of Two Systems (LIFE and D-Light)

    by F.J.F. Herth, A. Ernst, H.D. Becker

    Background: Autofluorescense (AF) bronchoscopy is an established method to detect dysplasia and carcinoma in situ (CIS). Several different systems are currently available. Objectives: This study aimed to directly compare the LIFE system (Xillix Technologies, Vancouver, Canada) and the D-light system (Storz, Tuttlingen, Germany). Methods: In a prospective study performed between May 1999 and October 2000, we examined patients with risk factors for lung cancer that underwent bronchoscopy with both (LIFE and D-light) systems in a crossover design. The findings were classified into normal, abnormal and suspicious lesions by independent investigators and then compared. Results: This study comprised 332 patients (220 males, 112 females, mean age 62.7 years, range 40–85); 1,117 biopsies were studied (mean biopsy rate 3.4/patient). In 817 biopsies, mucosal areas were classified as normal with respect to control biopsy specimens, 113 as abnormal and 187 as suspicious using AF bronchoscopy. The histological examination showed normal tissue in 850 cases, in 55 cases scarring or inflammation, in 62 meta- or dysplasias, in 11 carcinomas in situ and in 127 invasive tumors. In only 5 cases, classifications were found to be different between the two systems (2 normal, 2 dysplasias, 1 invasive tumor). The mean time for the LIFE system examination amounted to 11.7 min (range 6.2–19.5) and for the D-light system to 7.4 min (range 4.3–11.9). This difference was statistically significant (p < 0.001). Conclusion: Both systems yielded comparable results. The examination time was significantly shorter with the D-light system, which may be explained by the more comfortable handling and the direct switch between white light and AF imaging. Different trials using either methodology could be compared directly.


  • Transthoracic Ultrasound

    by F.J.F. Herth, H.D. Becker

    Sonography (US) has inherent limitations for thoracic imaging because sound waves are reflected by bone and air space (such as in lung parenchyma). However, US is less expensive and more convenient than computed tomography (CT) or magnetic resonance imaging (MRI); it provides immediate information with real-time imaging, and can give information not available from a standard radiograph. This review describes the utility and limitations of US and compares US with radiography.


  • Endobronchial ultrasound-guided transbronchial lung biopsy in solitary pulmonary nodules and peripheral lesions

    by F.J.F. Herth, A. Ernst, H.D. Becker

    Transbronchial biopsy (TBBX) for peripheral lung lesions is usually performed with the help of fluoroscopy, but the yield varies widely. This feasibility study aimed to assess the ability of endobronchial ultrasound (EBUS) to provide imaging guidance for TBBX.In a prospective study, 50 consecutive patients referred for TBBX for peripheral lesions underwent fluoroscopy-guided and EBUS-guided TBBX in random order. Diagnostic yields were compared for both modalities and feasibility was assessed for EBUS.Diagnostic material was obtained in 80% of patients with EBUS and 76% of patients with fluoroscopy. There was a nonsignificant trend for EBUS to be better than fluoroscopy for lesions <3 cm in diameter. Four lesions could not be visualised with EBUS. There were no significant complications associated with the use of EBUS.Endobronchial ultrasound-guided transbronchial biopsy is feasible. It appears to be at least equivalent to fluoroscopy without the accompanying radiation exposure. Further large-scale studies are indicated to assess the possible role of endobronchial ultrasound as a potential imaging method of choice for the biopsy of peripheral lung lesions.


  • Endobronchial ultrasound in therapeutic bronchoscopy

    by F. Herth, H.D. Becker, J. LoCicero, A. Ernst

    Endobronchial ultrasound (EBUS) has been introduced as an adjunct to diagnostic bronchoscopy as it allows evaluation of the submucosal and parabronchial structures. Its use in therapeutic bronchoscopy has not been assessed. A large observational study of the value of EBUS in therapeutic bronchoscopy is presented here.From January 1998–January 2001 all patients undergoing therapeutic bronchoscopy and EBUS were evaluated prospectively. Patient demographics, indication for bronchoscopy, interventional treatments used and changes in therapy as influenced by the use of EBUS were documented. A total 2,446 therapeutic bronchoscopies were performed. In 1,174 cases EBUS was used (29% mechanical tumour debridement, 20% airway stenting, 13% Neodymium:yttrium aluminium garnet (Nd:YAG) laser use, 23% argon plasma coagulation, 11% brachytherapy, 2% foreign body removal and 2% endoscopic abscess drainage).EBUS guided or changed therapy significantly in 43% of cases. Changes included adjustment of stent dimensions, termination of tumour debridement when nearing vessels, and referral for surgical interventions rather than endoscopic treatment. Complications associated with EBUS use were minimal. No patient undergoing EBUS guided tumour destruction experienced severe bleeding or fistula formation.In summary, endobronchial ultrasound was easily performed and changed or guided therapeutic decisions during therapeutic bronchoscopic procedures in a substantial number of cases. As this may result in better outcomes, it has become a standard adjunct in the authors practice.


  • Durchführbarkeit der Stressechokardiographie zur Früherkennung der Anthracyclin-induzierten Kardiomyopathie

    by F. Herth, M. R. Schulz, C. Manegold, H. D. Becker

    Hintergrund: Anthracycline sind Bestandteil verschiedener aktuell in Anwendung befindlicher Chemotherapieregime (aCT). Die Hauptnebenwirkung Kardiotoxizität stellt das größte Risiko für die Patientengruppe mit aCT dar. Die Stressechokardiographie (SE) ist eine etablierte Methode, um die linksventrikuläre Funktion in Ruhe und unter Belastung zu prüfen. Diese Studie bearbeitet die Frage, ob SE zur Verlaufsbeobachtung unter aCT eingesetzt werden kann. Patienten und Methodik: Patienten mit bösartigen Thoraxtumoren wurden vor und nach Ende der aCT einer medikamentösen Stressechokardiographie unterzogen. Ergebnisse: 30 Patienten wurden in die Studie eingeschlossen und die Daten verglichen. Vor der aCT betrug die mittlere LVEF in Ruhe 59 % und bei Ausbelastung 71 %. Wandbewegungsstörungen wurden nicht beobachtet. Nach der aCT (mittlere aCT-Dosis 408 mg, [Range 256 - 549 mg], mittlere Anzahl Therapiezyklen 4,4 [Range 4 - 7]) betrug die LVEF in Ruhe 58 % und bei Ausbelastung 68 % (nicht signifikant), Wandbewegungsstörungen waren nicht darstellbar. Schlussfolgerung: SE kann zur Verlaufsbeobachtung der linksventrikulären Funktion bei den Patienten unter aCT angewandt werden. In den in dieser Arbeit verwendeten Kumulativdosen kam es zu keiner Kardiotoxizität. Bei der SE handelt es sich um eine kostengünstige und sichere Screeningmethode. Background: Early evidence of drug induced cardiomyopathy is of great importance in oncological treatment, especially for application of Anthrazyklines. Stress echocar-diography (SE) has been proven to be of value in determining left ventricular function at rest and under stress. This study was performed to investigate the cardiac function under Anthrazykline-chemotherapy (aCT). Patients and methods: Patients with malignant thoracic tumors and indication for aCT underwent pharmacological SE (infusion of increasing dobutamin-doses, 5 µg/kg/bw in 3 minute-steps) before starting aCT. Left ventricular ejection fraction (LVEF) and wall motion were measured. If the tumor decreased and the patients underwent 4 or more cycles of CT, at the end of the last CT another SE investigation was performed. Results: 30 patients (20 men, 15 women; mean age 52, range 28 - 71) were included and the data were compared. Before aCT the mean LVEF was 59 % at rest and 71 % at maximum load, no disturbances of wall motion could be observed. After the end of aCT (mean dose 408 mg, range 256 - 549; mean 4.4 cycles, range 4 - 7) the LVEF was 58 at rest and 68 at maximum load (not significant) and there were also no disturbances of motion. Conclusion: SE is an alternative to echocardiography at rest in assessment of left ventricular function in patients receiving Anthrazykline-CT. With the doses applied no patient developed cardiomyopathy. So we consider SE a cost-effective method and safe for patients.